Exagen Inc. (XGN)
Nasdaq · Services-Medical Laboratories · Services · CIK 1274737 · fiscal year ends in Dec
Closing price $8.59 on 30 Oct 2026; 52-week range $2.65 to $11.83.
Key figures
The last twelve months reported, with the latest price and balance sheet.
- Revenue, last twelve months
- $71.1M
- Revenue growth
- 20.8%
- Net income, last twelve months
- -$18.9M
- Earnings per share
- -$0.81
- Gross margin
- 58.6%
- Operating margin
- -18.6%
- Net margin
- -26.6%
- Free cash flow
- -$7.6M
- Return on equity
- -154.9%
- Market value
- $207.7M
- Cash
- $24.6M
- Debt
- $22.8M
- Debt to equity
- 1.87
- Shares outstanding
- 24.2M
Financial statements
Revenue, profit and cash flow by fiscal year, each year linked to its annual report.
| Fiscal year | Year end | Revenue | Operating income | Net income | EPS | Free cash flow | Filing |
|---|---|---|---|---|---|---|---|
| FY2025 | 31 Dec 2025 | $66.6M | -$14.1M | -$20.0M | -$0.93 | -$14.3M | 10-K filed 10 Mar 2026 |
| FY2024 | 31 Dec 2024 | $55.6M | -$13.6M | -$15.1M | -$0.83 | -$13.8M | 10-K filed 11 Mar 2025 |
| FY2023 | 31 Dec 2023 | $52.5M | -$22.8M | -$23.7M | -$1.34 | -$15.3M | 10-K filed 18 Mar 2024 |
| FY2022 | 31 Dec 2022 | $45.6M | -$46.1M | -$47.4M | -$2.77 | -$36.5M | 10-K filed 20 Mar 2023 |
| FY2021 | 31 Dec 2021 | $48.3M | -$24.1M | -$26.9M | -$1.68 | -$22.6M | 10-K filed 22 Mar 2022 |
By quarter
| Quarter | Quarter end | Revenue | Net income | EPS |
|---|---|---|---|---|
| Q2 FY2026 | 30 Jun 2026 | $19.9M | -$3.2M | -$0.13 |
| Q1 FY2026 | 31 Mar 2026 | $17.3M | -$4.0M | -$0.17 |
| Q4 FY2025 | 31 Dec 2025 | $16.6M | -$4.7M | -$0.20 |
| Q3 FY2025 | 30 Sep 2025 | $17.2M | -$7.1M | -$0.31 |
| Q2 FY2025 | 30 Jun 2025 | $17.2M | -$4.4M | -$0.21 |
| Q1 FY2025 | 31 Mar 2025 | $15.5M | -$3.8M | -$0.20 |
| Q4 FY2024 | 31 Dec 2024 | $13.7M | -$3.8M | -$0.20 |
| Q3 FY2024 | 30 Sep 2024 | $12.5M | -$5.0M | -$0.28 |
Company events
The newest 8-K filings of 74 held.
| Filed | Form | Event | Items |
|---|---|---|---|
| 4 Aug 2026 | 8-K | Results | 2.02, 9.01 |
| 9 Jun 2026 | 8-K | Shareholder vote | 5.07 |
| 11 May 2026 | 8-K | Results | 2.02, 9.01 |
| 23 Apr 2026 | 8-K | Leadership change | 5.02, 9.01 |
| 10 Mar 2026 | 8-K | Results | 2.02, 9.01 |
| 12 Jan 2026 | 8-K | Results, Other events | 2.02, 8.01, 9.01 |
| 4 Nov 2025 | 8-K | Results | 2.02, 9.01 |
| 29 Jul 2025 | 8-K | Results | 2.02, 9.01 |
| 17 Jul 2025 | 8-K | Leadership change, Other events | 5.02, 8.01, 9.01 |
| 11 Jun 2025 | 8-K | Shareholder vote | 5.07 |
| 9 May 2025 | 8-K | Other events | 8.01, 9.01 |
| 8 May 2025 | 8-K | Material agreement, Other events | 1.01, 8.01, 9.01 |
Every filing
The newest filings with the SEC of 197 held.
| Filed | Form | Period |
|---|---|---|
| 4 Aug 2026 | 10-Q | 30 Jun 2026 |
| 4 Aug 2026 | 8-K | 4 Aug 2026 |
| 9 Jun 2026 | 8-K | 9 Jun 2026 |
| 12 May 2026 | S-8 | – |
| 11 May 2026 | 10-Q | 31 Mar 2026 |
| 11 May 2026 | 8-K | 11 May 2026 |
| 27 Apr 2026 | ARS | 31 Dec 2025 |
| 27 Apr 2026 | DEFA14A | – |
| 27 Apr 2026 | DEF 14A | 9 Jun 2026 |
| 23 Apr 2026 | 8-K | 17 Apr 2026 |
| 10 Mar 2026 | 10-K | 31 Dec 2025 |
| 10 Mar 2026 | 8-K | 10 Mar 2026 |
Insider trades
Form 4 trades by officers, directors and 10% owners, last 12 months.
| Traded | Insider | Type | Shares | Price | Value | Held after | Form 4 |
|---|---|---|---|---|---|---|---|
| 19 Oct 2026 | Chernett Jorey, 10% owner | Purchase | 14,000 | $7.46 | $104.4K | 2,618,540 | 20 Oct 2026 |
| 16 Oct 2026 | Aballi John, President and CEO | Sale outside a trading plan | 34,294 | $7.87 | $269.8K | 805,540 | 19 Oct 2026 |
| 1 Sep 2026 | Black Jeffrey G., Chief Financial Officer | Sale outside a trading plan | 20,614 | $7.22 | $148.8K | 323,339 | 2 Sep 2026 |
| 3 Mar 2026 | Aballi John, President and CEO | Sale outside a trading plan | 15,698 | $3.62 | $56.8K | 687,299 | 4 Mar 2026 |
| 24 Feb 2026 | Aballi John, President and CEO | Sale outside a trading plan | 11,430 | $3.61 | $41.3K | 702,997 | 25 Feb 2026 |
| 24 Feb 2026 | Black Jeffrey G., Chief Financial Officer | Sale outside a trading plan | 1,584 | $3.61 | $5.7K | 267,442 | 25 Feb 2026 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| Filed | Holder | Schedule | Stake | Shares |
|---|---|---|---|---|
| 27 May 2026 | Parian Ultreia LP | 13G | 5.3% | 1.3M |
| 20 May 2026 | Chernett Jorey | 13G amended | 9.9% | 2.4M |
| 17 Feb 2026 | RTW Investments, LP | 13G amended | 4.9% | 1.1M |
| 11 Feb 2026 | NMSIC Co-Investment Fund, L.P. | 13G amended | 6.04% | 1.4M |
| 4 Feb 2026 | Chernett Jorey | 13G | 5.4% | 1.2M |
Short interest
Shares sold short and not yet bought back, on each FINRA settlement date.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 673.9K | -4.37% | 1.82 |
| 30 Sep 2026 | 704.6K | -11.96% | 2.46 |
| 15 Sep 2026 | 800.3K | -7.37% | 3.59 |
| 31 Aug 2026 | 864.0K | -8.12% | 2.55 |
| 14 Aug 2026 | 940.4K | +4.04% | 1.5 |
| 31 Jul 2026 | 903.9K | -7.67% | 4.17 |
| 15 Jul 2026 | 979.0K | +20.36% | 4.48 |
| 30 Jun 2026 | 813.4K | +28.42% | 3.41 |
Funds that hold it
From each fund's latest Form 13F.
68 funds held it at 30 Jun 2026: 22 added and 24 trimmed in the quarter. The largest:
| Fund | Shares | Value | Change in the quarter |
|---|---|---|---|
| Wexford Capital LP | 792,855 | $3.7M | 0 |
| Nano Cap New Millennium Growth Fund L P | 675,000 | $3.1M | +90,000 |
| First Eagle Investment Management, LLC | 613,930 | $2.9M | – |
| Vanguard Capital Management LLC | 612,832 | $2.8M | -65,820 |
| FourWorld Capital Management LLC | 596,528 | $2.8M | +156,578 |
| Silvercrest Asset Management Group LLC | 514,761 | $2.4M | -23,109 |
| Kennedy Capital Management LLC | 485,048 | $2.3M | -8,612 |
| Mink Brook Asset Management LLC | 475,944 | $2.2M | +106,917 |
| Jane Street Group, LLC | 322,502 | $1.5M | +85,767 |
| Acadian Asset Management LLC | 310,084 | $1.4M | -379,030 |
Peers
Companies in the same industry.
- Natera, Inc. (NTRA): revenue $2.7B, market value $59.5B
- Labcorp Holdings Inc. (LH): revenue $14.6B, market value $29.4B
- Quest Diagnostics Inc. (DGX): revenue $11.8B, market value $27.7B
- Guardant Health, Inc. (GH): revenue $1.2B, market value $23.9B
- Caris Life Sciences, Inc. (CAI): revenue $989.6M, market value $9.7B
- Grail, Inc. (GRAL): revenue $165.3M, market value $6.4B
- RadNet, Inc. (RDNT): revenue $2.3B, market value $5.8B
- BillionToOne, Inc. (BLLN): revenue $397.4M, market value $5.3B
- CareDx, Inc. (CDNA): revenue $497.4M, market value $4.6B
- Veracyte, Inc. (VCYT): revenue $561.9M, market value $4.0B